Rainer Boxhammer

A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

Katharina A. Mayer, Eva Schrezenmeier, Matthias Diebold et al. · New England Journal of Medicine · 2024 · 150 citations · Full text

Life Sciences, Immunology, Nephrology +15

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Pedro Horna, Grzegorz S. Nowakowski, Jan Endell et al. · Blood · 2019 · 54 citations

Medicine, Oncology, Pathology +14

α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

Katharina Teiluf, Christof Seidl, Birgit Blechert et al. · Oncotarget · 2014 · 48 citations · Full text

Medicine, Hematology, Nuclear Medicine +11

Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway

Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner‐Herold et al. · Leukemia · 2018 · 43 citations

Medicine, Immunology, Pharmacology +14

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt et al. · Blood · 2016 · 38 citations

Medicine, Hematology, Oncology +16